COMP <GO>
NPCE vs JNJ // GROSS PROFIT MARGIN
Neuropace Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: NPCE 2
— JNJ 8
▲ GROSS PROFIT MARGIN LEADER: NPCE
LAST: $13.01 (+0.62%) • MKT CAP: $446.6M
gross-margins
77.20%
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
gross-margins
67.90%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NPCE VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NPCE | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 77.20% | 67.90% | +9.30 | NPCE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -23.00% | 25.50% | -48.50 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.54% | 2.97% | -5.51 | JNJ | /fcf-yield <GO> |
| Operating Margin | -16.30% | 34.70% | -51.00 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -21.50% | 28.50% | -50.00 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 25.10% | 6.00% | +19.10 | NPCE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 5.59 | -5.39 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 8/9 | -3.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 39.3 | 62.1 | -22.81 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 23.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $446.6M | $662.49B | -$662.05B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NPCE REV | JNJ REV | NPCE GROSS % | JNJ GROSS % | NPCE FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $100.0M | $94.19B | 77.2% | 67.9% | -$11.3M | $19.70B |
| FY 2024 | $79.9M | $88.82B | 73.9% | 69.1% | -$18.3M | $19.84B |
| FY 2023 | $65.4M | $85.16B | — | — | -$19.7M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NPCE // BETA —
JNJ // BETA 1.08